Haemonetics Corp

Market Summary

USD81.98+0.04

Market Closed

0.05%

HAE Stock Price

View Fullscreen

HAE RSI Chart

HAE Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

32.41

Price/Sales (Trailing)

3.36

EV/EBITDA

15.06

Price/Free Cashflow

20.88

HAE Price/Sales (Trailing)

HAE Profitability

EBT Margin

12.10%

Return on Equity

14.11%

Return on Assets

5.96%

Free Cashflow Yield

4.79%

HAE Fundamentals

HAE Revenue

Revenue (TTM)

1.2B

Revenue Y/Y

6.96%

Revenue Q/Q

2.2%

HAE Earnings

Earnings (TTM)

128.3M

Earnings Y/Y

-24.97%

Earnings Q/Q

-39.31%

Price Action

Last 7 days

-1.8%

Last 30 days

-3.8%

Last 90 days

-7.6%

Trailing 12 Months

-2.9%

How does HAE drawdown profile look like?

HAE Financial Health

Current Ratio

3.06

HAE Investor Care

Shares Dilution (1Y)

0.27%

Diluted EPS (TTM)

2.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.2B	1.2B	1.2B	0
2022	993.2M	1.0B	1.1B	1.1B
2021	870.5M	903.4M	933.8M	953.2M
2020	988.5M	945.6M	902.5M	883.9M
2019	967.6M	976.7M	987.7M	999.3M
2018	903.9M	922.3M	938.5M	951.8M
2017	886.1M	887.1M	892.2M	898.4M
2016	908.8M	905.4M	905.9M	900.4M
2015	910.4M	899.3M	891.4M	893.0M
2014	938.5M	943.5M	935.3M	925.0M
2013	892.0M	935.1M	952.6M	947.4M
2012	727.8M	733.8M	772.5M	828.7M
2011	676.7M	684.2M	696.8M	711.2M
2010	645.4M	654.4M	664.1M	675.8M
2009	597.9M	609.8M	621.7M	633.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for HAE

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 01, 2023	galvin roy	sold (taxes)	-13,822	86.39	-160	president, global plasma & bc
Oct 20, 2023	strong stewart w	sold (taxes)	-10,686	89.05	-120	president, global hospital
Oct 20, 2023	basil michelle l	sold (taxes)	-17,542	89.05	-197	evp and general counsel
Sep 15, 2023	miller laurie a.	sold (taxes)	-18,833	90.11	-209	svp, human resources
Sep 12, 2023	strong stewart w	sold	-20,668	90.65	-228	president, global hospital
Sep 11, 2023	lingamneni anila	sold	-207,450	90.00	-2,305	evp, chief technology officer
Sep 05, 2023	dockendorff charles j	sold	-895,651	87.68	-10,215	-
Aug 04, 2023	bryant diane m	acquired	-	-	2,226	-
Aug 04, 2023	dockendorff charles j	acquired	-	-	2,226	-
Aug 04, 2023	kroll mark w	acquired	-	-	2,226	-

Which funds bought or sold HAE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Nov 24, 2023	DEUTSCHE BANK AG\	reduced	-1.5	638,449	18,173,500	0.01%
Nov 22, 2023	Graham Capital Management, L.P.	sold off	-100	-482,062	-	-%
Nov 21, 2023	Walleye Capital LLC	new	-	202,182	202,182	-%
Nov 21, 2023	COMERICA BANK	reduced	-21.72	1,909,310	1,910,310	0.01%
Nov 17, 2023	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-15,108,900	-	-%
Nov 16, 2023	Financial Gravity Asset Management, Inc.	sold off	-100	-730	39.00	-%
Nov 16, 2023	Orion Capital Management LLC	new	-	23,828	23,828	0.01%
Nov 15, 2023	HARBOUR INVESTMENTS, INC.	unchanged	-	222	4,479	-%
Nov 15, 2023	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	reduced	-0.6	11,000	253,000	-%
Nov 15, 2023	Toroso Investments, LLC	added	12.19	60,571	396,571	0.01%

Latest Funds Activity

Are funds buying HAE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HAE

No. of Funds

Schedule 13G FIlings of Haemonetics Corp

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	capital research global investors	11.8%	5,956,064	SC 13G/A
Feb 09, 2023	vanguard group inc	10.36%	5,242,836	SC 13G/A
Feb 06, 2023	wellington management group llp	7.97%	4,034,753	SC 13G/A
Jan 26, 2023	blackrock inc.	11.7%	5,898,620	SC 13G/A
Jan 20, 2023	blackrock inc.	11.7%	5,898,620	SC 13G/A
Apr 08, 2022	capital research global investors	10.7%	5,452,006	SC 13G
Feb 14, 2022	neuberger berman group llc	7.59%	3,876,521	SC 13G/A
Feb 11, 2022	capital research global investors	4.0%	2,049,133	SC 13G/A
Feb 10, 2022	vanguard group inc	9.55%	4,880,936	SC 13G/A
Feb 10, 2022	wellington management group llp	10.83%	5,537,538	SC 13G/A

Recent SEC filings of Haemonetics Corp

View All Filings

Date Filed	Form Type	Document
Nov 03, 2023	4	Insider Trading
Nov 02, 2023	8-K	Current Report
Nov 02, 2023	10-Q	Quarterly Report
Oct 24, 2023	4	Insider Trading
Oct 24, 2023	4	Insider Trading
Oct 12, 2023	8-K/A	Current Report
Oct 10, 2023	8-K	Current Report
Sep 18, 2023	4	Insider Trading
Sep 13, 2023	4	Insider Trading
Sep 13, 2023	4	Insider Trading

Peers (Alternatives to Haemonetics Corp)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	179.2B	40.0B	10.05%	-2.88%	34.72	4.48	-11.26%	-34.57%
BDX	71.3B	19.4B	-6.71%	1.22%	44.09	3.79	2.66%	-16.58%
BAX	18.2B	15.0B	11.91%	-35.29%	7.03	1.21	3.01%	209.09%
ALGN	16.8B	3.8B	-13.48%	11.82%	46.33	4.42	-1.48%	-28.97%
MID-CAP
HSIC	9.1B	12.6B	2.80%	-13.35%	19.86	0.72	-0.94%	-29.54%
BIO	9.1B	2.7B	7.69%	-22.67%	-57.06	3.34	-3.01%	97.36%
ATR	8.4B	3.4B	4.90%	20.89%	30	2.45	3.13%	18.17%
XRAY	6.6B	3.9B	-1.54%	1.10%	-30.43	1.69	-2.62%	73.28%
PDCO	3.1B	6.5B	5.03%	11.86%	14.6	0.48	1.83%	10.70%
AXNX	2.9B	342.6M	11.80%	-12.52%	-240.39	8.41	42.19%	84.14%
SMALL-CAP
AHCO	1.2B	3.1B	19.36%	-60.32%	-2.73	0.37	7.95%	-550.16%
ANIK	310.6M	163.3M	13.17%	-30.31%	-12.64	1.9	7.14%	-56.09%
ANGO	280.7M	335.9M	7.28%	-49.08%	43.55	0.84	4.71%	116.39%
APYX	88.3M	50.3M	4.17%	45.35%	-5.83	1.76	3.23%	20.81%
AEMD	4.2M	3.8M	13.42%	-61.23%	-0.36	1.11	17.30%	10.67%

Haemonetics Corp News

Latest updates

msnNOW • 27 Nov 2023 • 03:32 pm • 7 hours ago

Top buy and top sell ideas in each sector – Oppenheimer

Stocks Register • 25 Nov 2023 • 03:35 pm • 2 days ago

What Can Cerus Corp. (NASDAQ: CERS) Expect In 2023? – Stocks ...

Stocks Register • 18 Nov 2023 • 12:33 pm • 9 days ago

Haemonetics Corp. (HAE) Forecast: Revisiting The Past To Gain ...

San Francisco Chronicle • 02 Nov 2023 • 07:00 am • 25 days ago

Haemonetics: Fiscal Q2 Earnings Snapshot

Nasdaq • 25 Oct 2023 • 07:00 am • 33 days ago

Notable Wednesday Option Activity: RBLX, AVAV, HAE

The Business Journals • 10 Oct 2023 • 07:00 am • 48 days ago

Haemonetics to buy Canadian company for $253M - Boston ...

StockNews.com • 20 Jul 2023 • 07:00 am • 4 months ago

TRUMY: Are These 3 Medical Stocks a Safe Investment?

The Business Journals • 24 Jun 2022 • 07:00 am • 17 months ago

Haemonetics opens new facility near Pittsburgh International Airport ...

Banyan Hill Publishing • 08 Feb 2022 • 08:00 am • 21 months ago

Crypto Is Like the Internet in the Late '90s

ThinkMarkets • 15 Jun 2021 • 04:37 pm • 2 years ago

Our Contract Specifications - Get Trading

TMS Brokers • 13 May 2021 • 04:04 pm • 2 years ago

Akcje Boeing Co: Aktualny kurs - Bezpieczny Dom Maklerski TMS ...

AsiaOne • 28 May 2020 • 07:00 am • 3 years ago

Best US Exchange Traded Funds (ETFs) in 2020, Money News

The Business Journals • 11 Dec 2019 • 08:00 am • 3 years ago

After four decades in Braintree, Haemonetics moves to downtown ...

TMS Brokers • 16 Nov 2019 • 04:39 pm • 4 years ago

Euro Korona szewdzka - forex - Aktualny Kurs, Cena i Notowania ...

TMS Brokers • 09 Mar 2018 • 11:44 am • 5 years ago

Bezpieczne inwestowanie na rynku Forex | OANDA TMS Brokers

Financials for Haemonetics Corp

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	2.2%	318	311	304	305	297	261	265	260	240	229	225	240	209	196	238	259	253	238	249	247	242
Gross Profit	1.9%	171	167	156	159	158	142	136	139	123	108	82.00	120	106	90.00	114	128	127	116	111	111	112
Operating Expenses	19.0%	135	114	121	115	111	111	117	103	98.00	107	103	80.00	47.00	78.00	88.00	87.00	77.00	129	87.00	83.00	86.00
S&GA Expenses	12.2%	105	93.00	97.00	95.00	92.00	92.00	92.00	81.00	76.00	91.00	84.00	66.00	64.00	62.00	53.00	78.00	78.00	73.00	54.00	74.00	77.00
R&D Expenses	0.1%	13.00	13.00	16.00	13.00	11.00	11.00	13.00	10.00	11.00	13.00	11.00	8.00	7.00	8.00	9.00	7.00	7.00	7.00	9.00	9.00	9.00
EBITDA Margin	-	-	-	0.21*	-	0.19*	0.18*	0.17*	0.13*	0.13*	0.17*	0.19*	0.25*	0.26*	0.24*	0.21*	0.21*	0.20*	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	1.00	2.00	1.00	2.00	3.00	2.00	4.00	3.00	4.00	4.00	4.00	3.00
Income Taxes	-24.5%	8.00	11.00	3.00	9.00	8.00	6.00	6.00	8.00	5.00	1.00	-16.38	5.00	7.00	-2.55	4.00	8.00	8.00	-9.25	1.00	7.00	4.00
Earnings Before Taxes	-36.4%	33.00	52.00	33.00	42.00	41.00	25.00	15.00	31.00	20.00	-3.01	-27.40	37.00	55.00	8.00	22.00	38.00	45.00	-17.73	22.00	25.00	23.00
EBT Margin	-	-	-	0.12*	0.11*	0.10*	0.09*	0.06*	0.02*	0.03*	0.07*	0.08*	0.14*	0.14*	0.12*	0.09*	0.09*	-	-	-	-	-
Net Income	-39.3%	25.00	41.00	29.00	33.00	33.00	20.00	10.00	23.00	15.00	-4.45	-11.04	32.00	48.00	11.00	18.00	30.00	37.00	-8.48	21.00	-8.48	19.00
Net Income Margin	-	-	-	0.10*	0.08*	0.08*	0.07*	0.04*	0.02*	0.03*	0.07*	0.09*	0.12*	0.12*	0.10*	0.08*	0.08*	-	-	-	-	-
Free Cashflow	-	-	-	68.00	48.00	51.00	-3.47	33.00	36.00	23.00	-15.60	-10.09	57.00	21.00	4.00	36.00	59.00	-	-	-	-	-

Balance Sheet
(In Millions)

Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	2.5%	2,011	1,962	1,935	1,878	1,865	1,821	1,860	1,831	1,801	1,794	1,820	1,318	1,418	1,433	1,267	1,238	1,191	1,260	1,275	1,228	1,266
Current Assets	8.0%	866	802	770	706	716	688	756	729	699	684	694	668	760	759	604	583	568	615	576	516	553
Cash Equivalents	22.8%	351	286	284	224	241	215	259	237	192	173	192	189	279	276	137	126	112	190	169	155	200
Inventory	-1.2%	286	289	259	256	255	278	293	306	323	327	323	300	305	295	270	254	245	222	194	169	164
Net PPE	1.1%	308	304	311	313	308	288	258	239	224	215	218	240	240	243	253	268	264	277	344	351	345
Goodwill	-0.1%	465	466	466	466	465	466	467	468	469	466	466	216	215	217	8.00	211	211	211	211	211	211
Current Liabilities	11.5%	264	237	252	227	262	180	442	355	288	228	253	194	339	408	275	257	240	294	236	211	189
LT Debt, Current	0.0%	14.00	14.00	12.00	10.00	58.00	7.00	214	144	83.00	17.00	17.00	17.00	167	231	77.00	62.00	57.00	118	28.00	17.00	13.00
LT Debt, Non Current	-0.4%	749	751	754	757	760	763	559	633	698	767	691	293	297	297	306	310	314	318	322	327	331
Shareholder's Equity	3.4%	894	865	818	776	729	770	749	731	699	677	732	719	668	609	587	575	584	591	668	591	701
Retained Earnings	8.8%	309	284	253	224	204	222	202	193	169	155	158	169	137	89.00	79.00	70.00	86.00	99.00	161	141	194
Additional Paid-In Capital	1.2%	617	610	595	587	564	580	572	567	558	551	603	579	569	563	553	538	534	525	536	531	530
Shares Outstanding	0.1%	51.00	51.00	50.00	50.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	50.00	50.00	51.00	51.00	51.00	51.00	51.00	52.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	419.4%	99,124,000	19,086,000	79,611,000	64,415,000	87,039,000	41,993,000	68,050,000	62,433,000	43,460,000	-1,680,000	1,547,000	66,291,000	29,155,000	11,812,000	46,406,000	79,282,000	29,901,000	2,628,000	20,638,000	58,164,000	57,357,000
Share Based Compensation	-4.0%	6,706,000	6,989,000	7,058,000	7,491,000	5,735,000	5,299,000	5,097,000	6,455,000	5,979,000	6,828,000	7,110,000	6,287,000	5,952,000	6,167,000	5,399,000	5,325,000	5,000,000	4,730,000	4,445,000	4,782,000	4,582,000
Cashflow From Investing	-64.7%	-25,135,000	-15,261,000	-18,006,000	-36,500,000	-31,068,000	-58,214,000	-34,512,000	-15,462,000	-20,520,000	-15,851,000	-429,100,000	-9,581,000	37,135,000	-23,896,000	-45,135,000	-19,866,000	5,964,000	1,861,000	-13,217,000	-27,585,000	-48,082,000
Cashflow From Financing	-1099.3%	-7,172,000	-598,000	-1,603,000	-49,680,000	-25,686,000	-23,395,000	-8,765,000	-2,035,000	-3,315,000	-1,634,000	432,759,000	-149,940,000	-64,318,000	148,951,000	11,372,000	-46,153,000	-112,517,000	16,090,000	6,995,000	-76,207,000	-79,000
Buy Backs	-	-	-	-	-	75,000,000	-	-	-	-	-	-	-	-	-	-	50,000,000	50,000,000	75,000,000	2,500,000	75,000,000	-

HAE Income Statement

2023-09-30

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Oct. 01, 2022	Sep. 30, 2023	Oct. 01, 2022
Income Statement [Abstract]
Net revenues	$ 318,183	$ 297,485	$ 629,515	$ 558,943
Cost of goods sold	147,673	139,607	291,740	258,802
Gross profit	170,510	157,878	337,775	300,141
Operating expenses:
Research and development	12,665	10,896	25,313	21,798
Selling, general and administrative	104,901	92,029	198,386	184,256
Amortization of acquired intangible assets	7,222	8,221	14,695	16,588
Impairment of assets	10,419	0	10,419	0
Total operating expenses	135,207	111,146	248,813	222,642
Operating income	35,303	46,732	88,962	77,499
Interest and other expense, net	(2,471)	(5,673)	(4,540)	(10,946)
Income before provision for income taxes	32,832	41,059	84,422	66,553
Provision for income taxes	7,924	7,862	18,472	13,479
Net income	$ 24,908	$ 33,197	$ 65,950	$ 53,074
Basic income (loss) per share (in dollars per share)	$ 0.49	$ 0.65	$ 1.30	$ 1.04
Diluted income (loss) per share (in dollars per share)	$ 0.48	$ 0.64	$ 1.28	$ 1.03
Weighted average shares outstanding
Basic (in shares)	50,727	50,953	50,634	51,089
Diluted (in shares)	51,396	51,558	51,368	51,620
Comprehensive income	$ 21,721	$ 25,659	$ 63,626	$ 38,773

HAE Balance Sheet

2023-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Apr. 01, 2023
Current assets:
Cash and cash equivalents	$ 351,005	$ 284,466
Accounts receivable, less allowance for credit losses of $5,044 at September 30, 2023 and $4,932 at April 1, 2023	174,249	179,142
Inventories, net	285,830	259,379
Prepaid expenses and other current assets	54,660	46,735
Total current assets	865,744	769,722
Property, plant and equipment, net	307,766	310,885
Intangible assets, less accumulated amortization of $433,092 at September 30, 2023 and $417,422 at April 1, 2023	250,504	275,771
Goodwill	465,405	466,231
Deferred tax asset	4,745	5,241
Other long-term assets	117,111	106,975
Total assets	2,011,275	1,934,825
Current liabilities:
Notes payable and current maturities of long-term debt	13,566	11,784
Accounts payable	80,160	63,929
Accrued payroll and related costs	45,638	64,475
Other current liabilities	124,851	111,628
Total current liabilities	264,215	251,816
Long-term debt, net of current maturities	748,662	754,102
Deferred tax liability	34,807	36,195
Other long-term liabilities	69,931	74,715
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,740,389 shares at September 30, 2023 and 50,448,519 shares at April 1, 2023	507	504
Additional paid-in capital	616,960	594,706
Retained earnings	308,898	253,168
Accumulated other comprehensive loss	(32,705)	(30,381)
Stockholders’ equity:	893,660	817,997
Total liabilities and stockholders’ equity	$ 2,011,275	$ 1,934,825

About Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

CEO	Mr. Christopher A. Simon
WEBSITE	www.haemonetics.com
EMPLOYEES	3034

Haemonetics Corp Frequently Asked Questions

What is the ticker symbol for Haemonetics Corp?

Ticker symbol for Haemonetics Corp is HAE.

What is the market capital of Haemonetics Corp (HAE)?

As of Fri Nov 24 2023, market cap of Haemonetics Corp is 4.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HAE stock?

You can check HAE's fair value in chart. The fair value of Haemonetics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Haemonetics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HAE so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Haemonetics Corp stock overpriced or underpriced?

The fair value guage provides a quick view whether HAE is over valued or under valued. Whether Haemonetics Corp is cheap or expensive depends on the assumptions which impact Haemonetics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HAE.

What is Haemonetics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 24 2023, HAE's PE ratio (Price to Earnings) is 32.41 and Price to Sales (PS) ratio is 3.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HAE PE ratio will change depending on the future growth rate expectations of investors.

Market Summary

HAE Stock Price

HAE RSI Chart

HAE Valuation

HAE Price/Sales (Trailing)

HAE Profitability

HAE Fundamentals

HAE Revenue

HAE Earnings

Price Action

How does HAE drawdown profile look like?

HAE Financial Health

HAE Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for HAE

Which funds bought or sold HAE recently?

Latest Funds Activity

Schedule 13G FIlings of Haemonetics Corp

Recent SEC filings of Haemonetics Corp

Peers (Alternatives to Haemonetics Corp)

Haemonetics Corp News

Financials for Haemonetics Corp

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

HAE Income Statement

HAE Balance Sheet

About Haemonetics Corp

Haemonetics Corp Frequently Asked Questions

What is the ticker symbol for Haemonetics Corp?

What is the market capital of Haemonetics Corp (HAE)?

What is the fair value of HAE stock?

Is Haemonetics Corp stock overpriced or underpriced?

What is Haemonetics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)